bluebird bio (NASDAQ:BLUE) posted its quarterly earnings results on Thursday. The biotechnology company reported ($2.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.83) by $0.11, Bloomberg Earnings reports. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%.
Shares of BLUE stock traded down $6.20 during trading hours on Thursday, reaching $127.24. The stock had a trading volume of 436,808 shares, compared to its average volume of 525,829. bluebird bio has a twelve month low of $87.49 and a twelve month high of $236.17. The stock has a market cap of $7.42 billion, a PE ratio of -16.50 and a beta of 2.62.
In related news, insider Nick Leschly sold 7,374 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $113.64, for a total value of $837,981.36. Following the sale, the insider now owns 20,682 shares of the company’s stock, valued at approximately $2,350,302.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider David Davidson sold 7,600 shares of the stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $98.82, for a total transaction of $751,032.00. Following the completion of the sale, the insider now directly owns 15,559 shares in the company, valued at approximately $1,537,540.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,631 shares of company stock worth $3,897,763. Corporate insiders own 3.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “bluebird bio (BLUE) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS” was first posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.wkrb13.com/2019/02/22/bluebird-bio-blue-issues-quarterly-earnings-results-beats-expectations-by-0-11-eps.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Story: What is an investor looking for in an SEC filing?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.